The procurement of stem cells, which is a crucial source-material in biomedical research promising the development of novel therapies in regenerative medicine, is subject to regulation using generic and technology-specific provisions throughout Europe. The relevant national regulatory regimes, while they share common regulatory frames, exhibit considerable differences as a matter of the regulatory approach followed, the biological level regulated, or of the context in which technologies for stem cell procurement are regulated. This variety indicates that legal regulation may resort to different means so as to secure a connection with the technology regulated. It is proposed that for improving "regulatory connection" states should consider engaging in regulatory borrowing from other systems covering both generic and specific instruments of technology regulation.
Introduction
Stem cell technologies, including the procurement of stem cells for research or for therapeutic purposes, are subject to fairly extensive regulation in Europe both at national and supranational level. Predominantly, the relevant regulatory instruments deal with questions which usually appear in the regulation of emerging biomedical technologies, such as risk, quality and safety, the ethics of biomedicine and biomedical research, or the achievement of public health objectives. Stem cell technology-specific measures, if they are available, address matters which have direct connection with the procurement and use of stem cells in biomedicine. The most frequently regulated is the determining of the permitted sources of stem cells. In most countries, these and other relevant regulatory frames are covered as integral parts of broader measures regulating generic areas, such as assisted reproduction, tissue and cell donation, or biomedical research. Only a few states have adopted instruments which are dedicated per se to stem cell technologies. These address certain issues prioritised in the local and European bio-legal discourse -for example, the availability of supernumerary human embryos for stem cell procurement -rather than regulating the technological domain comprehensively.
In this article, we examine the different regulatory regimes in Europe through the different frames they employ in regulating stem cell procurement.
This comparative exercise is carried out to assess -considering the potential held by stem cell technologies in terms of future public health benefits, in particular their application in regenerative medicine -whether their regulation in stem cell technology-specific measures should be preferred over the use of general biomedical regulation. This issue bears relevance from the perspective of the broader dilemma specific to technology regulation, namely the ensuring of an adequate "connection" between rules and the technology regulated. The diversity of provisions governing the relevant regulatory frames as revealed in this article indicates that, in their current state, the regulatory systems examined operate as mixed regimes offering different -both generic and specificsolutions, which in turn suggests the availability of multiple practices in securing the connection between stem cell technologies and the diverse rules applicable to them. On this basis, there may be a case for considering inter-systemic regulatory learning and borrowing provided that, having regard to the significant public health benefits promised, the connection between rules and stem cell technologies is sought to be improved by regulators.
This article is structured as follows. Firstly, it examines the broader basis in regulatory theory for comparing the regulatory frames as covered in the different systems of biomedical technology regulation in Europe, namely the dilemma of connecting rules with the technology regulated and the related issue of choosing between generic or specific provisions to secure regulatory connection. This is then followed by a comparative overview of the frames of stem cell technology regulation in different European states with a focus on the regulation of stem cell procurement. The article closes with an analysis of the regulatory variety and trends revealed by the comparative exercise having regard to the considerable diversity of solutions and practices. The legal material and ideas discussed in this work follow from the legal mapping report prepared in the EUCelLEX research project financed from the EU 7th Framework Programme, which examined and compared the regulation of stem cell procurement in Canada and a select group of states in Europe. EUCelLEX: Cell-based regenerative medicine: new challenges for EU legislation and governance (Grant agreement no.: 601806), available at http://www.eucellex.eu (accessed 5 May 2017). The countries included were Austria, Belgium, Canada, France, Germany, Hungary, the Netherlands, and the United Kingdom. They were selected with a view to securing sufficient diversity in the research of national regulatory regimes. The scope of the project consequently determines the scope of analysis in this article.
Regulatory frames and technology regulation: A regulatory tango
When analysing the regulation of stem cell technologies and the technologies of stem cell procurement, 2 it must be borne in mind that this is a developing technological domain, which remains subject to debates and controversies from scientific, ethical and legal perspectives. In legal regulation, the area has given rise to an interesting, and from the perspective of the future of the technologies involved, crucial interplay between rules and the technologies regulated -akin to a dance of tango -which employs an exciting array of bio-legal constructions involving new terms, categorisations and entities. It is not only the widely discussed ethical implications which make the legal regulation of this domain challenging, but regulators -aiming to ensure that the rules are adequately connected to the technology regulated -also face considerable dilemmas when they select the terms and categorisations and develop, with their help, the frames of regulation. 3 In this interplay, law and legal regulation participate with limited capabilities. Its desire to distinguish between the different components of the technology and accordingly set up categorisations assigning prohibitive or 2 It is important to note that we speak about stem cell technologies in plural, indicating that there are indeed multiple technologies in question which may raise very different issues requiring regulatory intervention. The emergence of human embryonic stem cell (hESC) technology meant that bioethical issues, which had no relevance for blood stem cells or adult stem cells, in particular the protection of human (embryonic) life, had to be addressed. The more recently discovered possibility of creating induced pluripotent stem cells (iPSC), which promises the replacement of hESC technology, was heralded as offering a way out from the moral dead end street of hESC technology. See, in this regard, Kristina Hug and Göran Hermerén, "Do We Still Need Human Embryonic Stem Cells for Stem Cellbased Therapies? Epistemic and Ethical Aspects" (2011) 7(4) Stem Cell Reviews 761-774.
3
See the technological frames listed and the argument concerning a "fully inclusive approach" to regulating new health technologies, which means that regulation is effective and it is fully negotiated by all affected parties in Amanda Warren-Jones, "Mapping Science and New For instance, on the basis of their risks or ethical implications, the law will distinguish between acceptable and prohibited sources of stem cells, the different types of stem cells, or between the different uses of stem cells.
5
See also the Dutch proposal to allow the growing, under strict conditions, of human embryos beyond the generally applicable temporal restriction for the purposes of research on infertility, assisted reproduction and hereditary and congenital diseases available at https://www.theguardian.com/science/2016/may/28/netherlands-gives-green-light-for-growinghuman-embryos (accessed 4 November 2016), which challenges the well-established and wellentrenched fourteen-day rule concerning the permissibility of research on human embryos, infra n.
53-56.
With these uncertainties in mind, revisiting which regulatory frames are used by different regulatory regimes and how they -employing generic or technology-specific provisions regulating those frames -connect with the technology regulated is not only a justifiable, but also necessary exercise. In the stem cell domain, there are significant public health objectives at stake, as promised by the emerging biomedical area of regenerative medicine. Realising these should not be hindered by rules which are inadequately connected with the technology or with particular dimensions of that technology. The concept of connecting regulation to the technology in question was raised in the discourse in regulatory theory.
10
Its relevance was seen as being able to ensure that the "potential health, safety, environmental, social, ethical and regulatory issues" which may be raised by the technology in question are addressed, or alternatively that regulators are prepared to address these when they emerge.
11
It was suggested that for regulation to be able to fulfil this expectation it needs to demonstrate certain fundamental qualities, namely it has to be effective and meet the requirement of regulatory economy, and it has to be legitimate and democratic.
12
The discourse also raised that technology regulation, despite the different pressures arising in the context of making a connection with the technology regulated, must be able to uphold law's inherent values and the rule 10 The focus is on the correspondence between the legal text and its purposes and the forms and uses of the technology. The introduction of stem cell-specific instruments, when that was considered necessary, and the alternative of introducing stem cell-specific rules into generic measures seem to have followed different objectives in the different states. Protecting -mainly in vitro -human (embryonic) life serves as the main regulatory objective in most states, either explicitly (for example, Austria, Germany, Belgium and the Netherlands),
25
or implicitly (the UK and Hungary).
26
Advancing healthcare and biomedical research are presented as parallel objectives in a number of countries.
27
Regulating stem cells and their application appeared as a specific objective in a few states (for example, Germany, Belgium and France).
28
The regulation of stem cell technologies, stem cell procurement in particular, as a part of comprehensive codes governing health care and biomedical research, as in the case of France, necessarily means that regulatory intervention is subject to multiple and overlapping objectives with specific objectives influencing the regulation of particular domains within the code. For example, the protection of persons involved in donation, regulation of tissue and 25 And the protection of the woman involved (Germany, the Embryo Protection Act). The Belgian rules have a strong focus on the regulation of the fate of supernumerary embryos created in a parental project. The Dutch Embryo Act also contains extensive provisions on biomedical research using human embryos. The Netherlands has a separate act for the protection of human foetal life (the life of the human fruit) and for the procurement of human foetal tissue. cell procurement, or availability of human embryos for reproductive or for biomedical research purposes.
29
The differences between national regimes regulating matters that are directly relevant for stem cell procurement are most striking when the definitions provided in law for the human embryo are considered. These differences seem to have an impact on the particular orientation and overall character of national regulation.
30
The local definitions range from extremely broad to precise and detailed. Austrian law introduced the rather broad concept of "viable cells"
which gave way to a prohibitive, and not particularly effective, national regulatory framework.
31
German law provides a detailed regulation of the embryo and its potentiality as a fertilised and viable 
Protecting rights and values
In Europe, the incorporation of the relevant bioethical considerations into biomedical technology regulation -often rather explicitly and through restrictive 34 Potentiality refers to the ability of different cells to differentiate into different cell types. Curiously, potentiality and the distinction between different forms of potentiality, as a matter of producing clear and precise legal definitions, did not receive much attention in Europe neither at the national, nor at the European level. 35 Supra n. 28. 36 The Embryo Protection Act and the Stem Cell Act. 37 Human Fertilisation and Embryology Act 1990. 38 The definition applicable in law is that provided in art. 16-1 of the Civil Code which "guarantees the respect of every human being from the beginning of its life". 39 Act on Health Care. As an indication of achievable levels of regulatory detail, the Hungarian regime also regulates the fate of "unlawfully donated", "refused" and "damaged" human embryos. 40 In Belgium, in three separate measures regulating the procurement and use of human bodily material, regulating assisted human reproduction and regulating research on in vitro human embryos. In the Netherlands, in the Embryo Act.
or prohibitive rules -is one of the dominant 41 regulatory frames. 42 This is particularly visible in the central regulatory distinctions used in legislation and also in the corresponding lists of restricted and prohibited activities ( Table 2) 
43
The outcome of these balancing exercises is largely affected by the aforementioned, ethically influenced, regulatory distinctions and categorisations made in the different measures. prohibiting -subject to exceptions -research on human embryos, hESC and hESC lines to a general rule which permits research on human embryos and hESC provided that it has been duly authorised. 43 The Oviedo Convention provides the common basis in Europe for such balancing exercises. See arts.
15 and 16 on the requirement of balancing between the risks and the benefits, the obligation to seek for alternative solutions, and the benchmark of ensuring the justifiability and the necessity of the intervention, which provisions also form part of the ethics-and human rights-based frame of technology regulation.
The most pertinent regulatory distinctions concern the use of human biological material, including human embryos, 
50
Hungarian law regulates a right of disposal over supernumerary embryos and the legal assumption that in case the right of disposal has not been exercised they should be put into deposit for further use.
51
The UK secures their availability by defining specifically the legal category of in vitro embryos.
52
48 In Belgium, their availability, donation, storage and use as regulated in the Act on Medically Assisted Reproduction and on the Fate of Supernumerary Embryos and Gametes. The act, and the Act on Research on In Vitro Human Embryos, gives a specific definition for supernumerary embryos as human embryos created in a parental project which were not implanted into the female womb. It also defines supernumerary gametes as gametes which were procured in a parental project but were not used (the act distinguishes between gamete providers and donors, the former referring to a person from whom gametes are procured for research purposes and the latter to a person who donates gametes for a parental project). The Dutch Embryo Act mentions the procuring of hESC as one of the legitimate objectives of embryo donation. 49 German law applies a distinction between human embryos and pluripotent stem cells, and prohibits the use of human embryos for research purposes under German jurisdiction. The Austrian concept of "viable cells", because of its general scope and its failure to distinguish between the different stages and forms of human embryonic development, provides a controversial legal basis for the prohibitive regime established (supra n. 31, 46). Austrian law also lacks the concept "supernumerary embryos" which, read in light of the relevant strict legislative provisions, further supports the conclusion that under law human embryos are not available as sources of stem cells. The legal status of imported stem cells, including hESC -Austrian law lacking provisions for this purpose -is less certain, and they may be available for research. Where the use of supernumerary embryos for research purposes is permitted, national regulation resorts to the following means of introducing ethics-based boundaries for conduct. Belgian law uses a legal distinction between human embryos and foetuses at eight weeks of embryonic development, which needs to be interpreted together with the rule which prohibits research on embryos after the fourteenth day of their development.
53
UK law recognises a similar rule which prohibits the keeping or using of an embryo after the appearance of the primitive streak (not later than the end of the period of fourteen days beginning with the day when the gametes are mixed, not counting any time during which the embryo is stored).
54
Hungary applies a twelve-week rule to separate embryos and foetuses, which needs to be applied together with the provision which allows research embryos to be kept alive for fourteen days.
55
The law in the Netherlands relies on a distinction between human embryos, foetuses and "human fruit", which needs to be read together with the prohibition on allowing the development of in vitro embryos beyond two weeks.
56
The national measures contain further, predominantly ethics-based tissue donation and procurement. 58 Similarly, while the principle of informed consent is recognised in the different national laws, its details, for instance the actual scope of the consent given or the formalities of providing consent, are regulated differently.
59
The most notable of these are the French provisions which in certain circumstances apply specific procedural and institutional, and sometimes substantive limitations.
60
Hungarian law also subjects giving and obtaining informed consent to specific formal and substantive conditions in particular situations.
61
A further shared requirement is that interventions, including the procurement of hESC, must be scientifically justifiable, conform to scientific standards, or be subject to scientific supervision.
62
Some states adopted a particularly detailed regulation of this requirement.
63
As a general benchmark, the regulatory systems investigated, although in different ways, require that human conduct in the biomedical research context must be proportionate and necessary. 64 The French regime provides an important locally specific example for the regulation of legally secured information rights of individuals and the parallel information obligations of the relevant institutional actors.
There are other country-specific value-influenced restrictions in different areas of regulation, which may affect -as parts of the general regulatory framework -the availability of certain source-materials for stem cell procurement. As seen in Table 2 , most national regimes include restrictions on the number of embryos created in a parental project, which rely, in one form or another, on a test of necessity. In connection with the earlier mentioned right of disposal over supernumerary embryos, Hungarian law recognises the possibility of refusing the donation of embryos in cases when their use for the declared purpose within the time available is unlikely and when it is likely that a human being will develop from the embryo. 
68
The commercial advertising of the donation and the mediation of viable cells and gametes in the context of assisted human reproduction processes is also prohibited.
69
Belgian law also contains an explicit ban on publicising, except when it is the interest of public health protection, the donation of human bodily material.
70
French law includes a prohibition on receiving remuneration for activities associated with tissue and cell procurement.
71
Hungary also applies a prohibition on providing or asking modifications (for example, Austria and the Netherlands). 76 There are others which implemented the directive with some structural adjustments so as to ensure that its requirements are duly integrated into existing national regulatory frameworks (for example, France and Germany).
77
Finally, there are regimes which incorporated EU rules with both structural and substantive adjustments made to national law (for example, the UK and Belgium).
78
These differences in the implementation strategy followed by individual Member States suggest considerable divergences regarding the relevance in national law and policy of the domain regulated, and the approaches pursued in the application and enforcement of the rules in question. 
Institutionalisation and proceduralisation
The national regulatory systems examined all operate an institutional framework for the ethical and other expert (for example, biomedical or technological) supervision of stem cell related activities, including stem cell procurement, and they provide for regulated procedures governing particular aspects of those activities, such as securing research authorisation or obtaining informed consent.
Again, in part, this is the outcome of the implementation of the relevant EU obligations which, in regulating risk, and quality and safety, place considerable emphasis on putting in place effective institutions and procedures. 
Local diversity
Expressing local diversity in the regulation stem cell technologies provides an inevitable theme for national regulation. 83 As bound by higher legal norms, or affected by judicial interpretation, national measures often express -in legal prohibitions or in legally prescribed balancing exercise between competing values or interests -genuinely local considerations. Austria serves as a curious example in this regard because the comparatively narrow scope of protection 81 See, for example, the particular Dutch approach of framing the relevant prohibitions and permissions as institutional and procedural rules in the Embryo Act. See also supra n. 65 on the particular national examples for regulating information rights and the corresponding institutional obligations. 82 See the specific provisions in France on obtaining informed consent, the Dutch rules on obtaining an authorisation for the "research protocol", or the German approach of regulating the conditions of decision-making in the national institutional and procedural framework. 83 For the EU level, this appears as the obligation to respect and accommodate local diversity, for example under the Tissues and Cells Directive, art. 4(3) recognises local discretion in deciding which specific type of human cells, especially which germ cells and embryonic stem cells may be used and which will be excluded from being used for human application.
offered under the rather generally elaborated constitutional standard 84 is not matched by the interpretations available to the applicable legislative text.
85
In contrast to the Austrian example, the deference of the Belgian constitutional court to the legislature in questions of biomedical ethics can be seen as having played a role in Belgium adopting an overall permissive and supportive regulatory framework.
86
Similarly, the provisions of the French Public Health Code seem to be in harmony with the approach of the Constitutional Council which deferred on matters of morality and policy in biomedicine to the discretion of the legislator, demanding nevertheless that an adequate balance is established between the competing rights and values laid down in the constitution.
87
In Hungary, the deference allowed under the Constitution has been used by the legislator to establish and maintain a relatively permissive regime for stem cell technologies, at least as far as hESC are concerned.
88
Conversely, the German constitutional court's uncompromising position on the right to life and human dignity seems to have found expression in the restrictive German measures.
89
In the UK, the particular features of the Human Fertilisation and Embryology Act 1990 do not follow from higher-ranking legal principles, rather from the outcomes of a broad and ambitious social discourse. 
94
The focus on regulating human embryology and the fate and uses of supernumerary embryos in a domain that is much broader than the procurement and the use of hESC can be regarded as suggesting uncertainties in the law, approaching an evolving technology with its categorisations and with its desire to subject the technology to law's formalised treatment. The complexities of establishing and maintaining regulatory connection that is effective, efficient, legitimate and democratic, achieving which, in the absence of definitive solutions, supports the need for cross-border regulatory learning and borrowing, were also made evident.
95
The national regimes examined do not seem to have secured the balance between these qualities of technology regulation. For instance, while the German regime contains a convincing 94 Supra n. 10-14. 95 The Canadian regime offers an interesting example. It combines hard legislation and soft governance. The detailed stem cell technology-specific rules are laid down in the non-binding soft instrument (the CIHR Guidelines), which rules, nonetheless, find their basis in the fundamental prohibitions laid down in legislation, the Assisted Human Reproduction Act. This solution seems to provide flexibility to regulation and it also pays attention to the demands of stakeholder compliance. 
98
Learning how other regulatory frameworks address generic and technology-specific frames of regulation can enhance the ability of permissive regimes to provide adequate responses to these problems.
Ultimately, as it follows from general dilemmas of technology regulation, the possibility offered by national regulatory variety for improving regulatory 97 See the discussion by Hoppe on the regulatory strategy of erecting prohibitive "firewalls" first and introducing subsequently individual exceptions from the thereby introduced prohibitions, Hoppe, "Innovative Tissue Engineering", supra n. 14, p. 121. 98 See, for example, the provisions regulating the donation of supernumerary embryos for research purposes, or the regulation of the creation of research embryos, when that is permitted.
frameworks and their connection with technology through inter-systemic regulatory learning and borrowing, must be exploited with responsibility.
Considering that the penultimate objective of regulatory intervention, as stated by the legal measures themselves, is the ensuring of public health protection through the development of novel biomedical therapies in regenerative medicine, the regulatory choices made have an impact on the access of patients to therapies to treat -often previously incurable -diseases. Regulation and its design are thought to influence the speed of therapeutic technologies moving from bench to bedside, thereby determining whether the best technologically possible therapies are available to patients in a way that justice and equity are ensured in the healthcare domain.
99
Furthermore, regulatory learning and borrowing must have regard to the values inherent in law and the rule of law itself.
100
Regulation, even when it is implemented in a volatile technological environment, is expected to provide certainty and clarity, especially as regards the rights and obligations of individuals and of the other stakeholders affected.
These qualities must be maintained on the longer run, especially when technological outputs are likely to be realised in long-term research and development processes.
It is unlikely that hard and fast choices will be available to regulators.
While generic measures are more likely to be sustainable on the longer term than technology-specific regulation, the overly extensive scope of such measures, their opaqueness and their lack of detail, especially when they are of low regulatory 99 See Hoppe, "Innovative Tissue Engineering", supra n. 14, p. 124. He argued that on this basis better targeted measures offering multiple, specialised avenues of technological development should be put in place. He, nevertheless, conceded enforcing the earlier mentioned dilemmas of regulatory connection that the success of regulatory intervention assumes that regulation is able to interact with technology in a way that the concepts used in regulation actually correspond with the technology, regulation actually understands the technology itself, and that regulation is actually prepared to address typical and untypical developments in the technological domain. 100 Supra n. 10, 13. quality, may unjustifiably impede research and the development of new therapies. The main problem with technology-specific measures, which on the positive side enable a comprehensive and informed regulation of technology, is that they may not provide the flexibility necessary for accommodating scientific and technological change. They may also give rise to fragmentation in the regulatory space jeopardising regulatory accessibility and clarity, and creating boundaries between different aspects of the same technology. On this basis, the responsibility which comes with regulation in the biomedical domain, instead of diminishing, increases the need for learning from other regulatory regimes, wherever they may be located on the prohibitive-permissive scale. The experiences as well as the strengths and weaknesses of other regimes enable reflecting upon the operation and the broader impact of national rules, which is all the more necessary considering that conflict and resistance characterise the engagement of the law with the technology and that the choices in this regard must address the difficulties and the inherent contradictions of connecting rules with the technology regulated.
